SGMONCMHealthcare·Biotechnology#357 in industry

Sangamo Therapeutics, Inc.

Reports in 14d· 2026-05-11

-44.7% · 90d

$0.21

+0.02 (+10.47%)

After-Hours $0.21(-0.00)

News

(1)

March 2026

Mar 30, 20260 months ago8-KHealthcare

SANGAMO THERAPEUTICS, INC — 8-K Filing

SGMOSANGAMO THERAPEUTICS, INC

# 🧾 What This Document Is This is an 8-K filing from Sangamo Therapeutics, a biotech company. It includes a press release (Exhibit 99.1) that serves as their official update to the market. Think of it as a "state of the union" report, detailing their recent scientific progress and financial health

Read summaryView on SEC EDGAR

Key Data

Market Cap$87.0M

Open$0.18

Prev Close$0.19

Day Range$0.18 – $0.21

52W Range$0.14 – $0.80

Volume11,187,172

P/E (TTM)—

EPS$-0.44

Dividend Yield—

Beta1.50

Revenue Growth88.40%

Price Target$3.75(+1685.7%)

Next Earnings2026-05-11(14d)

Analyst Ratings

Buy4 analysts

Buy 2Hold 2Sell 0

About

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; and SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A. Its preclinical development products focus on tauopathies, ALS/FTD, and huntington's diseases Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; and Open Monoclonal Technology, Inc. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. The company was incorporated in 1995 and is headquartered in Richmond, California.

Healthcare · Biotechnology

142 employees

www.sangamo.com